Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model

Septiara Putri, Ryan R. Nugraha, Eka Pujiyanti, Hasbullah Thabrany, Hanifah Hasnur, Novita D. Istanti, Diah Evasari, Afiatin

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Objective: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. Results: Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460).

Original languageEnglish
Article number359
JournalBMC Research Notes
Volume15
Issue number1
DOIs
Publication statusPublished - Dec 2022

Keywords

  • Cost-effectiveness
  • End stage renal disease
  • Hemodialysis
  • Peritoneal dialysis

Fingerprint

Dive into the research topics of 'Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model'. Together they form a unique fingerprint.

Cite this